Pharmacology & ToxicologybioRxivPreprint
Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitors
R. K. Singh, R. Sodhi, S. Sharma…·R. Tandon
The paper evaluates MK2 inhibitors as a safer alternative to p38 MAPK inhibitors for anti-inflammatory therapy by comparing their toxicity and efficacy in cell-based assays.
DOI 10.1101/2022.07.17.500377